(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 23.83% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is forecast to beat the US market's average forecast revenue growth rate of 7.56%.
Tg Therapeutics's revenue in 2023 is $189,772,000.On average, 4 Wall Street analysts forecast TGTX's revenue for 2023 to be $34,691,378,746, with the lowest TGTX revenue forecast at $33,950,680,669, and the highest TGTX revenue forecast at $35,672,213,199. On average, 4 Wall Street analysts forecast TGTX's revenue for 2024 to be $39,395,386,894, with the lowest TGTX revenue forecast at $33,897,687,143, and the highest TGTX revenue forecast at $48,584,464,224.
In 2025, TGTX is forecast to generate $56,647,050,611 in revenue, with the lowest revenue forecast at $48,140,832,710 and the highest revenue forecast at $69,542,646,529.